Myovant Sciences Ltd (MYOV) Upgraded to “Hold” by Zacks Investment Research

Zacks Investment Research upgraded shares of Myovant Sciences Ltd (NASDAQ:MYOV) from a sell rating to a hold rating in a research note published on Saturday morning.

According to Zacks, “Myovant Sciences Ltd. is a biopharmaceutical company. It focused on developing and commercializing therapies for women’s health diseases and other endocrine-related disorders, including advanced prostate cancer. The company’s product candidate consists of relugolix which are in clinical trial, an oral once-daily small molecule that acts as a gonadotropin-releasing hormone receptor antagonist. Myovant Sciences Ltd. is based in Hamilton, Bermuda. “

Separately, Evercore ISI initiated coverage on Myovant Sciences in a research note on Wednesday, August 16th. They set an outperform rating on the stock. One investment analyst has rated the stock with a hold rating and six have assigned a buy rating to the company. The stock has a consensus rating of Buy and an average target price of $18.20.

Shares of Myovant Sciences (NASDAQ MYOV) traded down 0.64% on Friday, hitting $12.47. 30,568 shares of the stock traded hands. The company’s 50 day moving average is $12.59 and its 200 day moving average is $12.15. Myovant Sciences has a one year low of $10.25 and a one year high of $14.27. The stock’s market cap is $758.72 million.

ILLEGAL ACTIVITY NOTICE: This report was originally posted by TrueBlueTribune and is owned by of TrueBlueTribune. If you are accessing this report on another website, it was illegally copied and reposted in violation of United States & international copyright and trademark law. The legal version of this report can be read at https://www.truebluetribune.com/2017/09/17/myovant-sciences-ltd-myov-upgraded-to-hold-by-zacks-investment-research.html.

Several institutional investors have recently made changes to their positions in MYOV. Wells Fargo & Company MN lifted its holdings in shares of Myovant Sciences by 331.9% during the 1st quarter. Wells Fargo & Company MN now owns 16,527 shares of the company’s stock valued at $194,000 after buying an additional 12,700 shares during the last quarter. Bank of New York Mellon Corp lifted its holdings in shares of Myovant Sciences by 36.3% during the 1st quarter. Bank of New York Mellon Corp now owns 23,784 shares of the company’s stock valued at $279,000 after buying an additional 6,330 shares during the last quarter. Oxford Asset Management acquired a new stake in shares of Myovant Sciences during the 1st quarter valued at about $303,000. JPMorgan Chase & Co. lifted its holdings in shares of Myovant Sciences by 30.6% during the 1st quarter. JPMorgan Chase & Co. now owns 83,070 shares of the company’s stock valued at $975,000 after buying an additional 19,474 shares during the last quarter. Finally, BB Biotech AG lifted its holdings in shares of Myovant Sciences by 3.4% during the 1st quarter. BB Biotech AG now owns 3,302,835 shares of the company’s stock valued at $38,775,000 after buying an additional 110,000 shares during the last quarter.

Myovant Sciences Company Profile

Myovant Sciences Ltd. is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for women’s health diseases and other endocrine-related disorders. Its main product candidate is Relugolix. Relugolix is an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone (GnRH) receptor antagonist that binds to and inhibits receptors in the anterior pituitary gland.

Analyst Recommendations for Myovant Sciences (NASDAQ:MYOV)

Receive News & Ratings for Myovant Sciences Ltd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myovant Sciences Ltd and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply